JPMorgan Chase & Co. Boosts Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $14.00

Key Points

• JPMorgan Chase & Co. has raised its price target for Amneal Pharmaceuticals from $12.00 to $14.00, indicating a potential upside of 43% from the stock's previous close.
• Amneal Pharmaceuticals has a consensus rating of "Buy" based on assessments from five analysts, although the average target price remains at $12.00.
• Institutional investors collectively own 31.82% of Amneal Pharmaceuticals, with significant recent purchases from firms like Nuveen LLC and Vanguard Group Inc.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) had its target price raised by equities research analysts at JPMorgan Chase & Co. from $12.00 to $14.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective would indicate a potential upside of 43.00% from the stock's previous close.

Separately, The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 price objective for the company. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $12.00.

Amneal Pharmaceuticals Stock Down 2.1%

NASDAQ AMRX opened at $9.79 on Tuesday. The business's fifty day simple moving average is $8.86 and its 200-day simple moving average is $8.19. The firm has a market cap of $3.07 billion, a PE ratio of 979.98 and a beta of 1.19. Amneal Pharmaceuticals has a 52 week low of $6.68 and a 52 week high of $10.34.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Research analysts expect that Amneal Pharmaceuticals will post 0.53 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Andrew S. Boyer sold 279,244 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total value of $2,619,308.72. Following the completion of the sale, the executive vice president directly owned 152,426 shares of the company's stock, valued at approximately $1,429,755.88. This represents a 64.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Nikita Shah sold 6,340 shares of the firm's stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $9.50, for a total value of $60,230.00. Following the sale, the executive vice president directly owned 146,403 shares of the company's stock, valued at $1,390,828.50. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 609,206 shares of company stock valued at $5,700,625 in the last 90 days. Insiders own 17.45% of the company's stock.

Institutional Trading of Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nuveen LLC acquired a new stake in shares of Amneal Pharmaceuticals during the 1st quarter worth approximately $19,581,000. Rubric Capital Management LP grew its holdings in shares of Amneal Pharmaceuticals by 9.1% during the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company's stock worth $94,737,000 after purchasing an additional 974,355 shares in the last quarter. Woodline Partners LP grew its holdings in shares of Amneal Pharmaceuticals by 165.2% during the 1st quarter. Woodline Partners LP now owns 1,504,095 shares of the company's stock worth $12,604,000 after purchasing an additional 937,035 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Amneal Pharmaceuticals by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock worth $132,092,000 after purchasing an additional 920,758 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Amneal Pharmaceuticals by 51.3% during the 1st quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company's stock worth $21,759,000 after purchasing an additional 880,471 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.